Feature | October 31, 2013

Boston Scientific Receives CE Mark for Lotus Valve System

TAVR device offers precise positioning and placement, offering physicians unprecedented control

heart valve repair hybrid or cath lab
October 31, 2013 — Boston Scientific Corp. has received CE mark for its Lotus Valve System, a transcatheter aortic valve replacement (TAVR) technology. This key approval offers an effective new treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement.
 
The Lotus Valve System is immediately available to select centers in Europe, with commercial site expansion accelerating as physicians and centers become fully trained. It is designed to provide physicians increased control during implantation and to help provide a more precise, predictable procedure. It is the only aortic valve device that can be assessed in its final position prior to release while maintaining the ability for the physician to reposition or fully resheath and retrieve the valve. The Lotus Valve System also incorporates Adaptive Seal technology designed to minimize aortic regurgitation.
 
"The ability to initially position the Lotus Valve precisely and, if needed, to easily reposition or fully retrieve the valve provides the operator with remarkable control," said Ian Meredith, director of MonashHeart at Monash Medical Centre, Melbourne, Australia and principal investigator, REPRISE II trial. "Combined with early and often complete elimination of aortic regurgitation as observed in REPRISE II, the unique features of the Lotus Valve technology represent a significant step forward in the percutaneous treatment of eligible patients with severe symptomatic aortic stenosis."
 
Data presented at the PCR London Valves course in September demonstrated the Lotus Valve System met the primary performance endpoint for the first 60-patient cohort and was implanted successfully in all patients with no cases of severe paravalvular regurgitation. In 76.1 percent of patients, there was no corelab adjudicated paravalvular regurgitation at six months.
 
"Results from the REPRISE II trial highlight the promise behind the Lotus Valve System, especially related to avoiding moderate or severe paravalvular leaks," said Nicolas Van Mieghem, M.D., Erasmus Medical Center, Rotterdam, Netherlands. "In addition to providing a new treatment option for TAVR, the Lotus Valve has the potential to improve clinical outcomes by minimizing paravalvular leaks."
 
The Lotus Valve System comes pre-loaded on a transfemoral delivery system, which is inserted through a small incision in the leg. Available in a 23 mm and 27 mm size, the Lotus Valve System can treat patients with aortic annulus sizes from 20 mm to 27 mm. The Lotus Valve System is an investigational device in the United States and Japan, and is not available for sale in those countries.
 
For more information: www.bostonscientific.com

Related Content

Feature | Business| April 28, 2016 | Dave Fornell
 
Technology | Stents Peripheral| April 27, 2016
Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering...
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings| April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Auris Surgical Robotics, acquisition, Hansen Medical
News | Robotic Systems| April 26, 2016
Auris Surgical Robotics Inc. and Hansen Medical Inc. announced that they have signed a definitive merger agreement...
Siemens Sensis Vibe, hemodyanamics system

Siemens released the Sensis Vibe hemodyanamics system at ACC.16. The newer system offers better integration of cath lab data into cath lab reports and the electronic medical record (EMR).

Feature | ACC| April 25, 2016 | Jon Brubaker, MBA, RCVT, Tom Watson, BS, RCVT, and Sabrina Newell MS, RCS
There were several trends seen in new cardiovascular technologies showcased on the expo floor at the 2016 American...
Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting| April 21, 2016
Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its novel, next-...
Boston Scientific, Fetch 2 aspiration catheter, Class 1 recall
News | Thrombectomy Devices| April 20, 2016
April 20, 2016 — Boston Scientific Corp. announced a U.S.
TAVR, Sapien 3, ACC.16
Feature | Heart Valve Repair| April 19, 2016 | Michael J. Rinaldi, M.D., FACC, FSCAI
The continuation of positive clinical trial data for transcatheter aortic valve repair (TAVR), showing it is equal to
ischemic postconditioning, STEMI patients, clinical outcomes, ACC.16
News | Cath Lab| April 19, 2016
A large randomized controlled trial of ischemic postconditioning in patients who had experienced ST-segment elevation...
STEMI, delayed or deferred stent implantation, DANAMI-3-DEFER trial, ACC.16
News | Cath Lab| April 18, 2016
Delayed or deferred stent implantation in patients showed no clinical benefit in patients experiencing the deadliest...
Overlay Init